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OBJECTIVES: To assess the quality of systematic reviews and clinical trials on women’s health recently published
in a Brazilian evidence-based health journal.
METHOD: All systematic reviews and clinical trials on women’s health published in the last five years in the
Brazilian Journal of Evidence-based Health were retrieved. Two independent reviewers critically assessed the
methodological quality of reviews and trials using AMSTAR and the Cochrane Risk of Bias Table, respectively.
RESULTS: Systematic reviews and clinical trials accounted for less than 10% of the 61 original studies on
women’s health published in the Sa˜o Paulo Medical Journal over the last five years. All five reviews were
considered to be of moderate quality; the worst domains were publication bias and the appropriate use of
study quality in formulating conclusions. All three clinical trials were judged to have a high risk of bias. The
participant blinding, personnel and outcome assessors and allocation concealment domains had the worst
scores.
CONCLUSIONS: Most of the systematic reviews and clinical trials on women’s health recently published in a
Brazilian evidence-based journal are of low to moderate quality. The quality of these types of studies needs
improvement.
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& INTRODUCTION
According to official data from a survey conducted in
2011 by the Brazilian Federal Medical Council, there are
204,563 practicing physicians in the country, 167,225 of
whom are specialists. Obstetricians-gynecologists (OB-
GYN) account for approximately 12% (22,815) of these
specialists, second only to pediatricians (27,232) (1). OB-
GYNs are directly responsible for over 5 million pregnan-
cies that occur each year in the country, in addition to the
care of over 97 million women in Brazil (2).
The importance of the continued medical education of
these physicians and of ensuring their access to the best
possible evidence is unquestionable. Articles published in
medical journals are important sources of information and
medical education for OB-GYNs and clinicians in general.
Although systematic reviews (SRs) and clinical trials (CTs)
are considered the highest level of evidence (3), the
quality of their methodology is not homogeneous, and
these publications should be as rigorously evaluated as
other types of studies (4). Thus, readers and users of SRs
and CTs should maintain a critical perspective and look
carefully at the methodological quality of the existing
publications.
SRs involve an exhaustive review of the literature to
answer a clearly defined clinical question using a systema-
tic, transparent and explicit methodology to identify, select,
critically appraise and synthesize all of the existing evidence
(4). Conducting an SR is a complex task, and flaws are
possible in this process; these factors lead to variations in
the quality of published SRs. A CT is a difficult study and
frequently involves a considerable number of researchers
and patients to answer a question on treatment or
prevention. In an attempt to avoid or minimize bias, a
rigorous methodology must be used. However, despite this
rigor, bias can compromise findings, and readers must keep
this in mind.
There is scarce literature on the quality of Brazilian SRs
and CTs in general and, to the best of our knowledge, there
have been no previous studies that analyzed the methodo-
logical quality of these types of studies on women’s health.
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Therefore, we set out to critically assess the quality of SRs
and CTs on women’s health recently published in a
Brazilian medical journal.
& MATERIALS AND METHODS
This observational study was performed by researchers of
the Brazilian Cochrane Center. Two independent investiga-
tors manually reviewed all electronic issues of the Sa˜o Paulo
Medical Journal (SPMJ-Brazilian Journal of Evidence-based
Health) published between 2008 and 2012 and available
through the SciELO database. All SRs and CTs focused on
women’s health were eligible for inclusion. The methodo-
logical quality and risk of bias of these articles were
assessed independently by each of the investigators. The
results were compared, and differences in ratings were
discussed until a consensus was reached. In the case of
disagreement, a third investigator was consulted.
To assess the quality of SRs, the authors used the AMSTAR
tool, which consists of 11 items that are rated as 0 or 1 (5). This
tool has good face and content validity for measuring the
methodological quality of SRs and requires approximately
10–15minutes for completion (6). AMSTAR has an acceptable
inter-rater agreement of the individual items, with a mean
kappa of 0.70 (95% confidence interval: 0.57, 0.83). The intra-
class correlation coefficient is 0.84 (95% confidence interval:
0.65, 0.92) (7). Using this tool, we classified the following 11
items for each SR: 1. a priori design; 2. duplicate study
selection and data extraction; 3. comprehensive literature
search; 4. inclusive publication status; 5. included/excluded
studies provided; 6. characteristics of included studies
provided; 7. quality assessment of studies; 8. study quality
used appropriately in formulating conclusions; 9. appro-
priate methods used to combine studies; 10. publication bias
assessed; and 11. conflict of interest stated. Each of these
items was classified as ‘‘Yes,’’ ‘‘No,’’ ‘‘Can’t answer’’ or ‘‘Not
applicable’’. We calculated the AMSTAR final score by
adding one point for each ‘‘Yes’’ answer and no points for
all other answers resulting in summary scores ranging from 0
to 11. For rating the overall quality of the SR, the following
categories were used: 0–4 = low-quality SR, 5–8 = moderate-
quality SR and 9–11 = high-quality SR (8).
To assess the quality of CTs, the authors used the Risk of
Bias Table, which was developed by the Cochrane
Collaboration and is available in the Cochrane Handbook
(9). This tool consists of seven domains: i) sequence
generation, ii) allocation concealment, iii) blinding of
participants and personnel, iv) blinding of outcome asses-
sors, v) incomplete outcome data, vi) selective reporting and
vii) other sources of bias. These domains are classified as
‘‘Yes’’ (i.e., low risk of bias), ‘‘Unclear’’ (i.e., uncertain risk of
bias) or ‘‘No’’ (i.e., high risk of bias). As recommended by the
CochraneHandbook, the overall classification of each CTwas
based on the rating of the first four domains (9). A study was
classified as having a high risk of bias when at least one of the
answers to these four items was ‘‘No.’’ When at least one of
the answers to these four items was ‘‘Unclear,’’ the trial was
classified as being at an unclear or moderate risk of bias.
& RESULTS
The SPMJ publishes six editions per year, with an average
of 11 articles per edition. Between the beginning of 2008 and
the third edition of 2012, a total of 196 articles were
published, of which 61 were related to women’s health,
including five SRs and three CTs. All SRs were on
gynecological topics: teriparatide for osteoporosis in post-
menopausal women (10), lapatinib for advanced or metas-
tasized breast cancer (11), comparative evaluation of digital
mammography and film mammography (12), colposcopic
triage methods for grade 3 cervical intraepithelial neoplasia
(CIN3) after a cytopathological diagnosis of a low-grade
squamous intraepithelial lesion (13) and risk of persistent
high-grade squamous intraepithelial lesion after an electro-
surgical excision with positive margins (14). Three of the
reviews focused on treatment (10,11,14), and two focused on
diagnosis (12,13). Three of these SRs presented meta-
analyses of their results (10,13,14).
The CTs were on ropivacaine plus clonidine for labor
analgesia (15), upper limb rehabilitation after breast cancer
mastectomy with preservation of the medial pectoral nerve
(16) and pelvic floor muscle training versus hypopressive
exercises for pelvic organ prolapse (17).
Description of the evidence presented in systematic
reviews
Teriparatide in postmenopausal women with osteo-
porosis. The authors analyzed five randomized trials
involving 3,504 women and concluded that compared to
placebo, the intermittent administration of 20 or 40 mg of
teriparatide reduced new vertebral and non-vertebral
fractures and improved whole-body and lumbar bone
mineral density without serious adverse effects.
Teriparatide (40 mg) was more effective than alendronate
(10 mg/day) in increasing whole-body, femoral and lumbar
bone mineral density but was similar to alendronate
regarding the occurrence of new fractures (10).
Lapatinib for the treatment of advanced or metastasized
breast cancer. The authors identified only one trial that
fulfilled the selection criteria, which included 324 women.
The review concluded that the combination of lapatinib
plus capecitabine was more effective than capecitabine
monotherapy for reducing the risk of cancer progression.
However, the authors emphasized the need for more
randomized clinical trials to assess the effectiveness of
lapatinib alone or in association with other drugs as first- or
second-line treatments for advanced breast cancer (11).
Comparative evaluation of digital versus film
mammography
This review included 11 studies and involved 190,322
digital and 638,348 film mammographies. The authors
concluded that digital mammography was slightly more
effective than film mammography in terms of cancer
detection rates. There were no significant differences in
recall rates between the two diagnostic methods, and the
characteristics of the tumors were similar in patients
screened by either type of mammography (12).
Colposcopic triage methods for detecting CIN3 after a
cytopathological diagnosis of low-grade squamous
intraepithelial lesions. Three studies involving a total of
1,766 women fulfilled the selection criteria and were
included in the review. The authors concluded that there
is currently no scientific evidence to support the hypothesis
that colposcopic triage using oncogenic human papilloma
virus (HPV)-DNA testing to detect CIN3 is better than
repeated cytological tests for women with low-grade
squamous intraepithelial lesions aged 35 years and older
(13).
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Risk of persistent high-grade squamous intraepithelial
lesions after electrosurgical excisional treatment with
positive margins. This review included four studies with
a total of 1,209 women. The authors concluded that the risk
of residual disease one year after electrosurgical excisional
treatment was approximately 11-fold higher in cases with
positive margins compared with cases with negative
margins. Patients with positive margins had a 29.4%
absolute risk of residual lesions during the first year and a
6% risk during the second year after the procedure. The
authors emphasized that to reduce the risks of residual
disease, attention should be given to correct indications,
appropriate surgical procedures, correct processing of the
excised specimen and appropriate choice of treatment. This
treatment choice should be individualized for each case. The
authors also recommended that additional studies were
needed to determine the best strategy for following up these
patients, particularly during the first year after excision (14).
Description of evidence from clinical trials
Labor analgesia with ropivacaine added to clonidine. The
authors randomized 32 women in labor to epidural analgesia
with either 15 ml of ropivacaine 0.125% or 15 ml of
ropivacaine 0.0625% plus 75 mg clonidine. The authors then
assessed maternal pain and neonatal effects. They concluded
that the pain score, sensory block level, duration of epidural
analgesia and Apgar scores did not differ significantly
between the two groups. However, infants of mothers who
received only ropivacaine had better neurological and
adaptative capacity scores (15).
Preservation of the medial pectoral nerve following
mastectomy due to breast cancer: impact on upper limb
rehabilitation. The authors of this study randomized 30
women with breast cancer to undergo modified mastectomy
with either preservation or sectioning of the medial pectoral
nerve. They assessed pectoral muscle strength and mass after
day 43. The women who underwent nerve preservation had
significantly higher muscle strength than those who
underwent nerve sectioning. No differences in muscle mass
or in abduction and flexion capacities of the homolateral
shoulder were identified between the groups (16).
Pelvic floor muscle training and hypopressive exercises for
treating pelvic organ prolapse in women. The authors
randomized 58 women with grade II pelvic prolapse to
either pelvic floor muscle training, hypopressive exercise or
a control group. At baseline and at 12 weeks after the
intervention, the authors used ultrasound to assess the
cross-sectional area of the levator ani muscle. They reported
a significant increase in this measurement in both
intervention groups but not in the control group. The
authors concluded that physiotherapy is effective in
increasing the cross-sectional area of the levator ani
muscle in women with pelvic organ prolapse and that
both modalities of physiotherapy are equally effective (17).
Critical appraisal of included studies
As depicted in Table 1, all five SRs mentioned an a priori
design, a comprehensive literature search and an inclusive
publication status and provided characteristics of included
studies and declared whether conflicts of interest were
present. On the other hand, none of the reviews considered
or mentioned the quality of included trials at formulating
their conclusions nor did they assess publication bias. Only
two SRs (10,12) provided a list of included/excluded studies
and clearly stated that duplicate study selection and data
extraction had been performed. Only two SRs assessed the
quality of included CTs: Riera et al. (11) used the Cochrane
risk of bias table (9), and Iared et al. (12) used the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS) tool
(18). Finally, only two SRs used an appropriate method to
combine studies (12,14).
As presented in Table 2 and summarized in Figure 1,
three CTs were classified as having a high risk of bias. One
CT (15) did not provide information on sequence generation
(selection bias), and two (16,17) did not report outcome
assessors (detection bias) or blind the participants and
personnel (performance bias).
& DISCUSSION
One of the most frequent methodological flaws of the SRs
was the failure to assess the quality of the studies. Authors of
SRs should grade the quality of their recommendations and
the strength of the evidence presented, which inevitably
depend on the quality of the original studies included in the
review. Out of the five published reviews, only two (11,13)
provided quality assessments of the primary studies, and
none mentioned this assessment in their conclusions.
Another frequent flaw was the failure to assess publication
bias, which was not investigated by any of the five reviews.
However, it should be noted that all of the reviews that
received a ‘‘zero’’ on the publication bias AMSTAR item
received this score because it was impossible to assess their
publication bias. Several SRs had no meta-analyses, and in
those studies where meta-analyses were performed, the
graphics included less than ten CTs. In this case, funnel plot
analyses to investigate publication bias are not recommended
by the Cochrane Handbook instructions (9).
Authoritative sources such as the Cochrane Handbook (9)
and PRISMA (19) guidelines emphasize that duplicate study
selection and data extraction are important for minimizing
the risk of bias in the selection of studies and the risk of
errors while transcribing data from the original studies.
Table 1 - Methodological quality of systematic reviews
focusing on women’s health published in the Sa˜o Paulo
Medical Journal between the beginning of 2008 and
2012.
AMSTAR item*
Systematic review 1 2 3 4 5 6 7 8 9 10 11 Total
Overall
Quality
Trevisani et al. (10) 1 1 1 1 1 1 0 0 0 0 1 7 Moderate
Riera et al. (11) 1 0 1 1 0 1 1 0 0 0 1 6 Moderate
Iared et al. (12) 1 1 1 1 1 1 0 0 1 0 1 8 Moderate
Correa et al. (13) 1 0 1 1 0 1 1 0 0 0 1 6 Moderate
Oliveira et al. (14) 1 0 1 1 0 1 0 0 1 0 1 6 Moderate
*AMSTAR (a measurement tool to assess systematic reviews) items are: 1. a
priori design; 2. duplicate study selection and data extraction; 3.
comprehensive literature search; 4. inclusive publication status; 5. list of
included/excluded studies provided; 6. characteristics of included studies
provided; 7. quality assessment of studies; 8. study quality used
appropriately in formulating conclusions; 9. appropriate methods used
to combine studies; 10. publication bias assessed; and 11. conflict of
interest stated.
Scale for item score: 1 = ‘‘Yes,’’ 0 = ‘‘No,’’ ‘‘Can’t answer’’ or ‘‘Not
applicable.’’ The following categories were used to rate the overall
quality of the reviews: score of 0–4 = low quality; 5–8 = moderate
quality; and 9–11 = high quality (8).
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However, only two of the SRs published in the SPMJ (10,12)
followed this recommendation. The lack of a list with
excluded studies could be due in part to editorial policies
and the need to limit the number of words per article. Only
two SRs used appropriate methods to combine studies
(12,14). However, it should be noted that the other three SRs
were graded as ‘‘zero’’ because it was impossible to perform
meta-analyses due to a lack of similar studies. This
conservative approach to assessing the quality of published
SRs has been used by other investigators performing similar
evaluations (20).
The most frequent methodological flaws of the three CTs on
women’s health were a lack of sequence generation informa-
tion, allocation concealment and patient blinding and person-
nel and/or outcomes assessors, all of which are considered
critical bias risk domains. Although there are several tools to
assess the risk of bias of CTs, including the Jadad scale (21) and
the Delphi list (22), we opted for the Cochrane tool, which is
widely used and internationally validated (9).
An implicit limitation of our study is that it assessed the
reporting quality of the SRs and CTs published in a
Brazilian evidence-based health journal and not necessarily
the actual methodological quality of these studies. If we had
contacted the original authors and asked for missing or
unclear methodological details, it is possible that their
studies could have been upgraded. Similarly, if the peer
reviewers and editors of the journal had asked the
researchers to address missing information before publish-
ing their manuscripts, the final reporting quality of these
eight studies would have likely been higher.
Due to the conclusions of this study, the ‘‘Instructions to
Authors’’ section of the SPMJ has been modified and
improved. Future authors who submit manuscripts for
potential publication in the SPMJ are now required to follow
internationally accepted guidelines, such as the PRISMA (19),
CONSORT (23), STARD (24), MOOSE (25) or STROBE (26)
recommendations, depending on the design of their study.
In summary, our findings indicate that most of the SRs
and CTs on women’s health recently published in a
Brazilian evidence-based health journal are of low to
moderate quality. As a result of this study, changes in the
‘‘Instructions to Authors’’ section have been made, and
higher standards have been adopted for future volumes of
this journal. To help improve the standards of our journals
and to ensure that our readers are consulting studies of high
methodological quality, we encourage other Brazilian
scientific journals to perform a similar critical appraisal of
the quality of the studies that they publish.
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Table 2 - Risk of bias of clinical trials on women’s health published in the Sa˜o Paulo Medical Journal between 2008 and
2012.
Bias/Study
Nakamura 2008
et al. (15)
Gonc¸alves 2009
et al. (16)
Bernardes 2012
et al. (17)
Was the allocation sequence adequately generated? No Yes Yes
Was allocation adequately concealed? Unclear Yes Unclear
Was knowledge of the allocated intervention adequately prevented during the
study? (patients and personnel)
Unclear Yes No
Was knowledge of the allocated intervention adequately prevented during the
study? (outcome assessors)
Unclear No No
Were incomplete outcome data adequately addressed? Yes Yes Yes
Are reports of the study free of suggestions of selective outcome reporting? Yes Yes Yes
Was the study free of other problems that could put it at a high risk of bias? Yes Yes Yes
‘‘Yes’’ = low risk of bias; ‘‘Unclear’’ = unclear risk of bias (moderate risk); ‘‘No’’ = high risk of bias.
According to the Cochrane recommendations (9), the answers to the first four items should be analyzed when performing the final classification of the
study. When at least one of the answers to these items is ‘‘No,’’ the study is classified as having a ‘‘High Risk of Bias’’; when at least one of the answers to
these items is ‘‘Unclear,’’ the study is classified as having a ‘‘Moderate or Unclear Risk of Bias.’’
Figure 1 - Summary of the risk of bias for clinical trials on
women’s health published in the Sa˜o Paulo Medical Journal
between 2008 and 2012.
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